This article is for educational purposes only and does not constitute investment advice. Prospective investors should consult qualified financial professionals and review official offering documents before making investment decisions. Investing in clinical-stage biotechnology companies carries substantial risk, including potential loss of entire investment.The Biotech IPO Window ReopensThe biotechnology IPO market demonstrated renewed vitality in 2024, producing 25 biotech listings compared to 19 in 2023, r ...

Key Takeaways BEAM reported Q4 loss of 10 cents per share as revenues jumped to $114.1 million, beating estimates.BEAM secured a $500M non-dilutive credit facility to support risto-cel launch in SCD.BEAM plans risto-cel BLA by the end of 2026. Its cash runway now extends into mid-2029.Beam Therapeutics (BEAM) incurred a loss of 10 cents per share in the fourth quarter of 2025 (excluding gain on sale of equity method investment), narrower than the Zacks Consensus Estimate of a loss of $1.13. The company had ...

Beam Therapeutics stock is surging to new heights today. What’s fueling BEAM momentum?Beam Surpasses Market ExpectationsBeam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectations of $12.567 million.“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development pa ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +91.15%. A quarter ago, it was expected that this company would post a loss of $0.98 per share when it actually produced a loss of $1.1, delivering a surprise of -12.24%.Over the last four quarters, the company has ...

Beam Therapeutics (NasdaqGS:BEAM) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAditya Lonial - Senior Managing DirectorAlec Stranahan - VP of Equity ResearchAmy Simon - Chief Medical OfficerGiuseppe Ciaramella - PresidentGopi Shanker - Chief Scientific OfficerHolly Manning - Vice President of Investor Relations and External CommunicationsJohn Evans - CEOKiran Musunuru - Professor of MedicineSravan Emany - CFOYannan Liu - Equity Research AssociateConference Call ParticipantsBrian C ...

Beam Therapeutics (NasdaqGS:BEAM) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAditya Lonial - Senior Managing DirectorAlec Stranahan - VP of Equity ResearchAmy Simon - Chief Medical OfficerGiuseppe Pino Ciaramella - PresidentGopi Shanker - Chief Scientific OfficerHolly Manning - Vice President of Investor Relations and External CommunicationsJohn Evans - CEOKiran Musunuru - Professor of MedicineSravan Emany - CFOYannan Liu - Equity Research AssociateConference Call ParticipantsBr ...

Beam Therapeutics (NasdaqGS:BEAM) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker14Good morning, and welcome to Beam Therapeutics conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at Beam's request. I would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications. Please go ahead.Speaker9Thank you, operator. G ...

Clinical Development - The company is developing risto-cel, an autologous HSC investigational therapy for sickle cell disease, with a Phase 1/2 clinical trial (BEACON) involving approximately 50 patients[657]. - Preliminary data from the BEACON trial showed mean HbF levels above 60% and a mean durable reduction in HbS below 40%[662]. - The company plans to submit a Biologics License Application (BLA) for risto-cel as early as year-end 2026[659]. - The company is conducting a Phase 1/2 clinical trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD), with updated clinical data expected in Q1 2026[663]. - BEAM-304 is a new liver-targeting LNP formulation for phenylketonuria (PKU), with plans to submit a regulatory application for a Phase 1/2 trial in 2026[665]. - The company is also developing BEAM-301 for glycogen storage disease Ia (GSDIa), with initial data from the trial expected in 2026[667]. - The median time to neutrophil engraftment in the BEACON trial was 17.5 days, with 29% of patients not requiring platelet transfusions post-treatment[662]. - The company has identified multiple targeted LNPs for in vivo delivery of gene editing payloads to HSCs, prioritizing this approach for sickle cell disease[660]. Financial Performance - License and collaboration revenue for the year ended December 31, 2025, was approximately $139.7 million, an increase of $76.2 million from $63.5 million in 2024[687]. - Research and development expenses increased to $409.6 million in 2025 from $367.6 million in 2024, reflecting a rise of $42.1 million[688]. - The accumulated deficit as of December 31, 2025, was $1.6 billion, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively[675]. - The company expects to continue incurring significant operating losses as it advances its preclinical and clinical development activities[676]. - Total operating expenses for the year ended December 31, 2025, were $523.4 million, compared to $479.1 million in 2024, indicating an increase of $44.4 million[685]. - The company has not generated any revenue from product sales and does not expect to do so in the near future, relying primarily on license and collaboration agreements for revenue[678]. - The company anticipates that general and administrative expenses will increase to support research and development and compliance with public company requirements[683]. - The company recorded a gain of $255.1 million on the sale of an equity method investment during the year ended December 31, 2025[685]. - General and administrative expenses increased to $113.8 million in 2025 from $111.5 million in 2024, with a $27.9 million rise in external research and development expenses[690]. - The company recorded a net cash used in operating activities of $345.1 million for the year ended December 31, 2025, compared to $347.2 million in 2024[707][710]. - Cash used in investing activities for 2025 was $121.4 million, primarily due to net purchases of marketable securities totaling $367.3 million[712]. - Net cash provided by financing activities in 2025 was $478.0 million, largely from the issuance of common stock and pre-funded warrants, generating $470.5 million[714]. - The company had $1.2 billion in cash, cash equivalents, and marketable securities as of December 31, 2025[703]. - The company anticipates significant operating losses and expenses as it advances preclinical and clinical development of product candidates[698]. Financing and Obligations - The financing agreement includes a senior secured term loan facility of up to $500 million, with an initial draw of $100 million on February 24, 2026[668]. - The Credit Facility matures on February 24, 2033, and bears interest at an annual rate equal to the 3-month SOFR plus 6.50%[668]. - The Financing Agreement requires maintaining liquidity of at least $40 million, increasing to $80 million and $125 million upon drawing Delayed Draw A and B, respectively, if market capitalization is below $1.75 billion[671]. - The Financing Agreement includes a Credit Facility with an initial draw of $100 million and additional amounts available upon achieving certain milestones[704]. - The company may owe up to $90.0 million in success payments to Harvard and Broad Institute based on increases in the per share fair market value of its common stock[705]. - The company has potential obligations to pay up to an additional $90.0 million in success payments to Harvard and Broad Institute, payable in cash or shares of common stock[723]. - Future minimum commitments under noncancelable operating leases amount to $210.1 million as of December 31, 2025[722]. - The company may owe up to an additional $89.0 million in development, clinical, and commercial milestones to former stockholders of an acquired life sciences company[726]. Market and Economic Conditions - The company has cash, cash equivalents, and marketable securities totaling $1.2 billion as of December 31, 2025, with primary exposure to interest rate sensitivity[745]. - The company is not currently exposed to significant market risk related to foreign currency exchange rates but may increase exposure through future contracts with international vendors[746]. - Inflation has not materially affected the company's financial statements to date, but future operations may be adversely impacted[747]. - The company is required to make success payments based on increases in the per share fair market value of its common stock, which are accounted for as derivatives[741]. - The company has significant estimates and judgments related to accrued expenses and prepaid research and development costs, impacting financial statements[743]. - Revenue recognition is based on ASC 606, with revenue recognized when control of promised goods or services is obtained by the customer[730]. - The company has not recognized any milestone or royalty revenue from its agreements to date[738].

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...